However, HIP1R can activate the anticancer immunity of T cells via lysosomal degradation of programmed cell death 1 ligand 1 (PD-L1) [169], implying that miR-23b and miR-27b may have a possibility to compromise cancer immune surveillance in vivo. The gene discussed is CD274; the disease is cancer.